Cytokinetics Inc CYTK

Healthcare Biotechnology

Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company specializes in muscle biology and the mechanics of muscle performance. It is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Its cardiac muscle contractility program is focused on the cardiac sarcomere. Its clinical-stage drug candidates are: aficamten, which is a next-in-class cardiac myosin inhibitor; omecamtiv mecarbil, which is a cardiac myosin activator; CK-586, which is an additional cardiac myosin inhibitor, and CK-136, which is a cardiac troponin activator. CK-586 is designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction.

NDAQ:CYTK - Post by User

Cytokinetics Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson May 23, 2024 5:15pm

55 Views

Post# 36054771

Overweight Recommendation Issued On CYTK By Barclays

Just In: $CYTK Overweight Recommendation Issued On CYTK By Barclays2024-05-23 07:15:08 ET Barclays analyst issues OVERWEIGHT recommendation for CYTK on May 23, 2024 05:37AM ET. The previous analyst recommendation was Overweight. CYTK was trading at $59.23 at issue of the analyst recommendation. The overall analyst consensus : BUY. C...CYTK - Overweight Recommendation Issued On CYTK By Barclays

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec